Regado Trims Workforce, Revamps Strategy on Trial Halt - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 3:30PM CDT
Regado (RGDO) has reduced its work force by almost 60%.
Catalyst Pharma Closer to Unconscionable Price Hike for Rare-Disease Drug
at The Street - Tue Sep 30, 6:20AM CDT
For the zero work done by Catalyst, LEMS patients will pay as much as $80,000 for the exact same drug they use now for a fraction of the cost.
Pacira Down on Receipt of FDA Warning Letter for Exparel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 1:38PM CDT
Pacira Pharmaceuticals, Inc.'s (PCRX) reveived a warning letter from the FDA's Office of Prescription Drug Promotion (OPDP) regarding certain promotional materials on Exparel.
Project Update, Awards, Appointment, Product Launch, and Sponsorship - Research Reports on D.R. Horton, Mallinckrodt, Illumina, Ventas and Capital One Financial
PR Newswire - Mon Sep 29, 7:30AM CDT
Today, Analysts Review released its research reports regarding D.R. Horton Inc. (NYSE: DHI), Mallinckrodt PLC (NYSE: MNK), Illumina Inc. (NASDAQ: ILMN), Ventas, Inc. (NYSE: VTR) and Capital One Financial Corporation (NYSE: COF). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6815-100free.
Emergent BioSolutions Initiates Pivotal Study on BioThrax - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 4:20PM CDT
Emergent BioSolutions (EBS) initiated a pivotal non-clinical study on BioThrax to support the licensure of the company's new modern facility, Building 55.
Progenics' Azedra Found Positive in Phase II Follow-Up Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 23, 5:10PM CDT
Progenics Pharmaceuticals, Inc. (PGNX) reported positive data from a long-term follow-up pivotal phase II study on its ultra-orphan radio-therapeutic candidate, Azedra, in patients suffering from malignant pheochromocytoma.
Supernus Confirms 2014 Outlook, Epilepsy Products in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 23, 3:55PM CDT
Supernus Pharmaceuticals, Inc. (SUPN) reaffirmed its 2014 guidance assuring that it will emerge profitable by year-end.
Mallinckrodt (MNK) Highlighted As Momo Momentum Stock
at The Street - Fri Sep 19, 9:14AM CDT
Trade-Ideas LLC identified Mallinckrodt (MNK) as a momo momentum candidate
Impax Rytary FDA Action Date Extended by Three Months - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 3:30PM CDT
The FDA has pushed back the PDUFA date for Impax Laboratories, Inc.'s Rytary by three months to Jan 9, 2015.
Alcobra (ADHD) Worth Watching: Stock Moves 5.1% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:25AM CDT
Alcobra (ADHD) was a big mover last session, with shares rising over 5% on the day.
Novo Nordisk's Tresiba Effective in Children & Adolescents - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 5:10PM CDT
Novo Nordisk (NVO) announced new positive data from the BEGIN YOUNG 1 study on Tresiba for type I diabetes in children and adolescents (1 year to <18 years).
Earnings, Market Activity, Investment Agreements, Study Data, and Product Deployment - Research Reports on Darden, XPO, Mallinckrodt, SJM and Honeywell
PR Newswire - Wed Sep 17, 7:40AM CDT
Today, Analysts Review released its research reports regarding Darden Restaurants, Inc. (NYSE: DRI), XPO Logistics, Inc. (NYSE: XPO), Mallinckrodt PLC (NYSE: MNK), St. Jude Medical Inc. (NYSE: STJ) and Honeywell International Inc. (NYSE: HON). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6529-100free.
NPS Pharmaceuticals' Natpara Gets Positive FDA Panel Vote - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 6:05PM CDT
The EMDAC of the FDA recommended the approval of NPS Pharmaceuticals' Natpara.
Can Mallinckrodt public limited (MNK) Keep the Earnings Streak Alive This Quarter? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 12, 7:54AM CDT
Mallinckrodt public limited could be a great candidate for another beat after a solid performance in the last two quarters.
Mylan to Acquire U.S. Rights to Arixtra for up to $300M - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 11, 4:20PM CDT
Mylan (MYL) is all set to acquire the U.S. commercialization, marketing and intellectual property rights to Arixtra injection from Aspen.
Actavis' Bystolic Combination Gets Negative FDA Panel Vote - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 3:45PM CDT
Actavis plc (ACT) announced that the FDA's CRDAC has voted against the approval (in the ratio of 6:4) of Actavis' fixed-dose combination (FDC) of Bystolic (nebivolol) and Novartis' (NVS) Diovan (valsartan).
Emergent BioSolutions Wins $29M Anthrax Vaccine Deal - Analyst Blog
Maharathi Basu - Zacks Investment Research - Wed Sep 10, 3:30PM CDT
Emergent BioSolutions (EBS) secured a federal contract worth up to $29 million.
Endocyte (ECYT) Worth Watching: Stock Soars 17% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 8:46AM CDT
Endocyte (ECYT) was a big mover last session, with shares rising just over 17% on the day.
Actavis' Antibiotic under FDA Review, Response in 1Q15 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 4:20PM CDT
Actavis plc (ACT) announced the acceptance of its new drug application for its antibiotic candidate, ceftazidime-avibactam, by the FDA.
Mallinckrodt (MNK) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 9:39AM CDT
Mallinckrodt (MNK) Shares March Higher, Can It Continue?